<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FONDAPARINUX SODIUM</span><br/>(fon-da-par'i-nux)<br/><span class="topboxtradename">Arixtra<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators &amp; anticoagulants</span>; <span class="classification">anticoagulant</span>; <span class="classification">low-molecular weight heparin</span><br/><b>Prototype: </b>Enoxaparin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, 10 mg/0.8 mL syringe</p>
<h1><a name="action">Actions</a></h1>
<p>Fondaparinux sodium causes antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. Fondaparinux selectively binds
         to ATIII, potentiating the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa by fondaparinux interrupts
         the blood coagulation cascade, inhibiting thrombin formation and, thus, thrombus development. Fondaparinux sodium does not
         inactivate thrombin (activated Factor II) and has no known effect on platelet function, therefore, it rarely causes thrombocytopenia.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Fondaparinux is effective in the prevention and treatment of deep-vein thrombosis. The laboratory value utilized to determine
         the effectiveness of the drug is the amount of anti-Xa assay expressed in mg.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis for DVT or pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery or abdominal surgery;
         treatment of acute DVT without PE with warfarin, treatment of PE with warfarin.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fondaparinux; active bleeding; GI bleeding; severe renal impairment with a creatinine clearance of 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment or disease; older adult; indwelling epidural catheter; dental disease, dental work; diabetic retinopathy;
         diverticulitis; endocarditis, epidural anesthesia; hemophilia, heparin-induced thrombocytopenia (HIT), hepatic disease, hypertension,
         idiopathic thrombocytopenia purpura (ITP); inflammatory bowel disease, lumbar puncture, spinal anesthesia; stroke, surgery;
         thrombocytopenia, thrombolytic therapy; vaginal bleeding, menstruation; peptic ulcer disease; pregnancy (category B); bleeding
         disorders including a history of GI ulceration, etc., history of heparininduced thrombocytopenia; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">DVT, Pulmonary Embolism Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span>
<i>&gt;50 kg</i> 2.5 mg q.d. starting at least 6 h postsurgery times 59 days; <i>for hip fracture patients,</i> up to 24 d additional use<br/><br/><span class="indicationtitle">Treatment of DVT, Pulmonary Embolism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span>
<i>, 5 mg; <i>50100 kg</i>, 7.5 mg; <i>&gt;100 kg</i>, 10 mg once daily <small>x</small> 59 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3050 mL/min, use with caution; <br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Consult physician about discontinuing other agents that may enhance the risk of hemorrhage prior to initiation of fondaparinux.</li>
<li>Give no sooner than 6 h after surgery.</li>
<li>Adjust doses in older adults based on renal function.</li>
<li>Inspect visually for particulate matter and discoloration prior to administration.</li>
<li>Do not expel the air bubble from the syringe before the injection.</li>
<li>Use prefilled syringe to inject into fatty tissue, alternating injection sites (e.g., between L and R abdominal wall).</li>
<li>Store at 25° C (77° F); excursions permitted to 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, edema. <span class="typehead">CNS:</span> Insomnia, dizziness, confusion, headache. <span class="typehead">CV:</span> Hypotension. <span class="typehead">GI:</span> Nausea, constipation, vomiting, diarrhea, dyspepsia, elevated LFTs. <span class="typehead">Endocrine:</span> Hypokalemia. <span class="typehead">Hematologic:</span> Hemorrhage, <span class="speceff-common">anemia,</span> hematoma. <span class="typehead">Skin:</span> Irritation at injection site, rash, purpura, bullous eruption. <span class="typehead">Urogenital:</span> UTI, urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">anticoagulants</span>, <span class="classification">antiplatelets</span>, <span class="classification">nsaids</span>, <b>aspirin</b> may increase risk of bleeding. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>ginkgo,</b>
<b>ginger</b> may potentiate bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed from SC injection site. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> Primarily in blood. <span class="typehead">Metabolism:</span> Negligible metabolism. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 18 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of bleeding or hemorrhage. If noted, withhold fondaparinux and notify physician immediately.</li>
<li>Monitor closely patients with epidural catheters for signs of paralysis below catheter level.</li>
<li>Withhold fondaparinux and notify physician if platelet count falls below 100,000/mm<sup>3</sup>.
         </li>
<li>Lab tests: Monitor baseline and periodic renal function rests; periodic CBC including platelet count, serum creatinine level,
            and stool occult blood tests. (Note: PT and aPTT are relatively insensitive measures of fondaparinux activity and unsuitable
            for monitoring.)
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to a health care provider: signs of unexplained bleeding such as: pink, red, or dark brown urine;
            red or dark brown vomitus; bleeding gums or bloody sputum; dark, tarry stools.
         </li>
<li>Learn proper injection technique if you are to self-administer this drug.</li>
<li>Do not take any OTC drugs without first consulting physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>